Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hoffmann-La Roche | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
While both conventional and advanced MRI techniques offer important insights into MS pathophysiology, important aspects of this inflammatory disorder are undetectable with existing MRI technology. In Multiple Sclerosis (MS), there is growing interest in PET as an imaging modality that can increase the investigator's understanding of the disease processes and may add to an understanding of MS phenotype, particularly when combined with advanced MRI techniques such as myelin water imaging.
This is an exploratory study. PBR28 PET scan is new, promising and exploratory endpoints in MS clinical trials, making sample size estimation difficult.
A separate pre-screening consent form will be issued for the TSPO rs6971 polymorphism and eGFR blood samples, a separate pre-screening step. Eligible participants, according to their TSPO rs6971 polymorphism will be presented a separate study consent form to continue into the clinical trial.
Study Assessments include 1 PET scan, 1 MRI scan, OCT, EDSS exam, physical exam, cognitive questionnaires, etc.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multiple Sclerosis (MS) patients | 3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy | ||
| Healthy Controls (HC) | 3 Healthy volunteers aged between 18-60 years of age |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Whole Brain PBR28 binding | To show an increase in 11C-PBR28 binding in all sub-types of MS compared to healthy controls. | January 2020 |
| Measure | Description | Time Frame |
|---|---|---|
| Myelin Water Imaging by MRI | To quantitatively measure the brain levels of water located within myelin | January 2020 |
| Optical Coherence Tomography | To correlate brain levels of inflammation measured by 11C-PBR28 with Retinal Nerve Fiber Layer (RNFL) thickness on Optical Coherence Tomography (OCT). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Exclusion specific to MRI (All MRI specific criteria is subject to conditions posed by the MRI technologist or radiologist):
Exclusion specific to OCT:
Not provided
Not provided
3 untreated RRMS, 3 untreated PPMS and 3 healthy controls
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Janice Jong | Contact | 604-827-1892 | janice.jong@ubc.ca | |
| Erin Gallinger | Contact | 604-827-1921 | erin.gallinger@ubc.ca |
| Name | Affiliation | Role |
|---|---|---|
| Robert L Carruthers, MD | MS Clinical Trials Group | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UBC MS & NMO Clinical Trials Group | Recruiting | Vancouver | British Columbia | V6T1Z3 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| January 2020 |
| MS Spectroscopy | To correlate brain levels of inflammation and myelin measured by PET with cognitive dysfunction in MS patients. | January 2020 |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |